{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:31Z","timestamp":1789506691303,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["101037867"],"award-info":[{"award-number":["101037867"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003761","name":"Universitair Medisch Centrum Utrecht","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128769","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:47:42Z","timestamp":1782575262000},"page":"128769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5\u201311\u00a0years old (CoVacc trial)"],"prefix":"10.1016","volume":"88","author":[{"given":"Cristina","family":"Prat-Aymerich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"Yeghiazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi Delan","family":"Pathirana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Abner","family":"Garcia Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurvin","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Loens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Jane","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Formiconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"van Hulst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeri","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Posch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Bruijning-Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild Bruun","family":"Mikalsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Dollner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Kristian","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Oberthuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Papaevangelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128769_bb0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/apa.15270","article-title":"Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults","volume":"109","author":"Ludvigsson","year":"2020","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.vaccine.2026.128769_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1985","article-title":"Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study","author":"Docherty","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128769_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamapediatrics.2020.4573","article-title":"Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: A systematic review and meta-analysis","volume":"175","author":"Viner","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.128769_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0025","series-title":"Vaccine schedule","author":"European Center for Disease Prevention and Control (ECDC)","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128769_bb0030","author":"GISAID"},{"key":"10.1016\/j.vaccine.2026.128769_bb0035","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0040","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053418","article-title":"Risk factors for severe COVID-19 in children","volume":"149","author":"Woodruff","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128769_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073639","article-title":"Hospital admissions linked to SARS-CoV-2 infection in children and adolescents: cohort study of 3.2 million first ascertained infections in England","author":"Wilde","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128769_bb0050","article-title":"Caracter\u00edsticas cl\u00ednicas de pacientes pedi\u00e1tricos con s\u00edndrome de dificultad respiratoria aguda asociado con COVID-19","volume":"79","author":"Marroqu\u00edn-Y\u00e1\u00f1ez","year":"2022","journal-title":"Bol Med Hosp Infant Mex"},{"key":"10.1016\/j.vaccine.2026.128769_bb0055","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13312","article-title":"SARS-CoV-2 seroprevalence trends in the Netherlands in the variant of concern era: input for future response","volume":"18","author":"Vos","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128769_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jpids\/piae062","article-title":"Bivalent Omicron BA.4\/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds","volume":"13","author":"Sher","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2026.128769_bb0070","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa2211031","article-title":"Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age","volume":"388","author":"Mu\u00f1oz","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0075","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.43.2400143","article-title":"Contact behaviour before, during and after the COVID-19 pandemic in the Netherlands: Evidence from contact surveys, 2016 to 2017 and 2020 to 2023","volume":"29","author":"Backer","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128769_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149154","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128769_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149150","article-title":"First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19","volume":"131","author":"Mazzoni","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128769_bb0090","article-title":"Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination","volume":"5","author":"Voss","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0095","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1093\/infdis\/jiaf007","article-title":"Effectiveness of mRNA COVID-19 Vaccines and Hybrid Immunity in Preventing SARS-CoV-2 Infection and Symptomatic COVID-19 Among Adults in the United States","volume":"231","author":"Feldstein","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128769_bb0100","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","article-title":"Myocarditis following COVID-19 mRNA vaccination","volume":"39","author":"Abu Mouch","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128769_bb0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/14760584.2023.2204154","article-title":"Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: A systematic review and meta-analyses","volume":"22","author":"Katoto","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128769_bb0110","doi-asserted-by":"crossref","first-page":"7745","DOI":"10.1038\/s41467-024-52038-6","article-title":"Influence of mRNA Covid-19 vaccine dosing interval on the risk of myocarditis","volume":"15","author":"Le Vu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128769_bb0115","series-title":"71030031000; Biobank Antwerp [BB190007], BBMR-ERIC, Belgian [BIORESOURCE]","author":"BE","year":"2026"},{"key":"10.1016\/j.vaccine.2026.128769_bb0120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/vaccines12101089","article-title":"Navigating the landscape of B cell mediated immunity and antibody monitoring in SARS-CoV-2 vaccine efficacy: tools, strategies and clinical trial insights","volume":"12","author":"O\u2019Reilly","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128769_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0294262","article-title":"Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening","volume":"18","author":"O\u2019Reilly","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128769_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2022.113345","article-title":"Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination","volume":"510","author":"Kenny","year":"2022","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2026.128769_bb0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3201\/eid3105.250021","article-title":"Detection of SARS-CoV-2 Reinfections Using Nucleocapsid Antibody Boosting","volume":"31","author":"Grebe","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128769_bb0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128769_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1327875","article-title":"Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children","volume":"14","author":"Verheul","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128769_bb0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1094727","article-title":"The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age","volume":"13","author":"Cinicola","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128769_bb0160","article-title":"COVID-19 mRNA vaccine tolerance and immunogenicity in hematopoietic stem cell transplantation recipients aged 5-11 years old-non-randomized clinical trial","volume":"11","author":"Matkowska-Kocjan","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128769_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092562","article-title":"Immune response following BNT162b2 mRNA COVID-19 vaccination in pediatric cancer patients","volume":"15","author":"Schmidt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2026.128769_bb0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijid.2023.02.017","article-title":"The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial","volume":"130","author":"Chantasrisawad","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128769_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s43856-025-00882-y","article-title":"Effectiveness of a single COVID-19 mRNA vaccine dose in individuals with prior SARS-CoV-2 infection: a systematic review","volume":"5","author":"Volkman","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJMoa2205011","article-title":"BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age","volume":"387","author":"Cohen-Stavi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128769_bb0185","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3390\/vaccines10111880","article-title":"Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis","volume":"10","author":"Sabu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128769_bb0190","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128769_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.12.028","article-title":"From rigid to rapid: rethinking clinical trial processes for emergency-ready clinical trials","author":"van Hout","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.128769_bb0200","series-title":"A phase 2, randomised trial to evaluate immunogenicity of a single versus two-dose primary vaccination regimen of the BNT162b2 mRNA vaccine in paediatric subjects with prior SARS-CoV-2 immunity","author":"Pathirana","year":"2025"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:39:14Z","timestamp":1789504754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"alternative-id":["S0264410X26005785"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128769","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5\u201311\u00a0years old (CoVacc trial)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128769"}}